Skip to main content
SpringerLink
Log in

Clinical characteristics and prognostic factors of prostate cancer with liver metastases

  • Research Article
  • Published:
Tumor Biology

Abstract

Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29 %. Eight (29.63 %) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37 %) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21:1323–60.

    Article  PubMed  Google Scholar 

  3. Guerin S, Hill C. Cancer epidemiology in France in 2010, comparison with the USA. Bull Cancer. 2010;97:47–54.

    CAS  PubMed  Google Scholar 

  4. Na YQ, Sun G, Ye ZQ, Sun YH, Sun ZY. Guideline of Chinese urological disease diagnosis and treatment. Beijing: People’s Health Publishing House; 2009.

    Google Scholar 

  5. Zheng RS, Zhang SW, Wu LY, Li GL, Ping Z, Hao J. Report of incidence and mortality in China Cancer Registries, 2008. China Cancer. 2012;21:1–12.

    Google Scholar 

  6. Whitmore Jr WF. Natural history and staging of prostate cancer. Urol Clin North Am. 1984;11:205–20.

    PubMed  Google Scholar 

  7. Pouessel D, Gallet B, Bibeau F, Avancès C, Iborra F, Sénesse P, et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int. 2007;99:807–11.

    Article  CAS  PubMed  Google Scholar 

  8. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, et al. Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). J Clin Oncol. 2012;30(suppl; abstr 4655).

  9. Marech I, Vacca A, Sivestris N, Gnoni A, Lorusso V (2013) Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: a case report. Onco Lett 5(6):1877-80 doi:10.3892/ol.2013.1275.

    Google Scholar 

  10. Caffo O, Gernone A, Ortega C, Sava T, Cartenì G, Facchini G, et al. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol. 2012;107:191–6.

    Article  PubMed  Google Scholar 

  11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.

    Article  CAS  PubMed  Google Scholar 

  12. Shao Q, Ouyang J, Fan Y, Xie J, Zhou J, Wu J, et al. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration. Cancer Lett. 2012;315:170–7.

    Article  CAS  PubMed  Google Scholar 

  13. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.

    Article  CAS  PubMed  Google Scholar 

  14. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer. 2000;88:2590–7.

    Article  CAS  PubMed  Google Scholar 

  15. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12:109–17.

    Article  CAS  PubMed  Google Scholar 

  16. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943–7.

    Article  CAS  PubMed  Google Scholar 

Download references

The study was supported by NSFC (81071787) and Tianjin Municipal Science and Technology Commission (08JCYBJC10300).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Interventional Oncology, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin, China

    HaiTao Wang, BaoGuo Li, PengYu Zhang & YanHong Yao

  2. Research Group of Evidence-based Clinical Oncology, Tianjin, China

    HaiTao Wang & BaoGuo Li

  3. Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

    HaiTao Wang & BaoGuo Li

  4. Tianjin Institute of Urological Surgery, Tianjin Medical University, Tianjin, China

    JiWu Chang

Authors
  1. HaiTao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. BaoGuo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PengYu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. YanHong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. JiWu Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to HaiTao Wang or JiWu Chang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, H., Li, B., Zhang, P. et al. Clinical characteristics and prognostic factors of prostate cancer with liver metastases. Tumor Biol. 35, 595–601 (2014). https://doi.org/10.1007/s13277-013-1083-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1083-6

Keywords

Search

Navigation